Ann: FDA grants broader orphan drug status to PTX100 for TCLs, page-41

Kras is a relatively new tech. But the FDA is becoming more and more familiar with it. Gaining confidence in bio markers that might guide to where Kras drugs may be successful.

PTX100 covers the broadest spectrum of the Kras drug being investigated at the moment.

https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug

Kras is being associated with many different cancers now. PTX100 may become more a platform drug.

Its starting to get a bit exciting around here.